ZG005 drug combo for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug combination (ZG005, Gecacitinib, and chemotherapy) for people with advanced solid tumors that cannot be removed by surgery. It aims to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 to 75.
- You must have a type of advanced solid tumor that has come back or spread and cannot be removed with surgery.
- You need to be in fairly good physical health (able to do light activities like walking or housework).
- Life expectancy of at least 3 months.
- You must understand the study and agree to join by signing a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial studies ZGGS18, a new medicine, in people with advanced solid tumors that either no longer respond to standard treatment or for whom standard treatment isn’t an option. The goal is to see how the drug works and what side effects it causes.
This trial is testing a new combination of two drugs (ZGGS18 and ZG005) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
This Phase 1 trial studies ZG0895.HCl, a new experimental treatment, in people with advanced solid cancers. It’s mainly to check safety and how the body responds, and it may help by shrinking or controlling tumors if the drug works.
This trial tests a new drug (ZG005) combined with two standard chemotherapy drugs (etoposide and cisplatin) for people with advanced neuroendocrine carcinoma that has spread or come back. The goal is to see if the combination works better than the standard treatment alone.
This trial is testing a new drug called ZG006 for people with advanced small cell lung cancer or neuroendocrine carcinoma. The study has two parts: first finding the right dose, then testing it in more people with neuroendocrine carcinoma.
This trial tests a new combination of two drugs, ZG005 and Gecacitinib, for people with advanced non-small cell lung cancer that cannot be treated with surgery or radiation. The goal is to see if the combination can shrink or slow the cancer.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.